SIGA Posts $3.5M Q1 Loss, Secures $13M and $26M TPOXX Deals
SIGA posted a Q1 net loss of $3.5 million on $6.2 million revenue, widening operating loss to $5.3 million. SIGA secured an exclusive MENA license with Hikma and plans $13 million in oral TPOXX shipments in Q2 and $26 million in IV deliveries to the U.S. stockpile by Q3.
1. Q1 Financial Performance
SIGA reported total revenues of $6.2 million for the three months ended March 31, 2026, down from $7.0 million in Q1 2025, with product sales falling from $5.8 million to $3.5 million. Operating loss widened to $5.3 million from $2.3 million year-over-year, resulting in a net loss of $3.5 million, or $0.05 per share.
2. Upcoming TPOXX Deliveries
The company plans to deliver approximately $13 million of oral TPOXX treatment courses to an Asia Pacific customer in Q2 under a multi-year contract and to ship about $26 million of IV TPOXX courses to the U.S. Strategic National Stockpile by the end of Q3, fulfilling the 2025 BARDA procurement order.
3. MENA License and Dividend
In March 2026, SIGA granted Hikma MENA FZE exclusive rights to register and commercialize oral TPOXX in the Middle East and North Africa, with SIGA as sole supplier. On March 26 the company declared a $0.60 per share special cash dividend, paid April 23 to shareholders of record on April 7.